

Carboplatin

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

PHYSICIAN INFORMATION			PATIENT INFORMATION			
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on			
Specialty:	* DEA, NPI or TIN:		this form are completed.*			
Office Contact Person:			* Patient Name:			
Office Phone:			* Cigna ID:	* Date of Birth:	* Date of Birth:	
Office Fax:			* Patient Street Address:			
Office Street Address:			City:	State:	Zip:	
City:	State:	Zip:	Patient Phone:			
Urgency: Standard Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)						
Medication Requested:						
Dose: F	Dose: Frequency of therapy: Duration of therapy:					
What is your patient's current height? What is your patient's current weight?						
Where will this medication be obtained? <pre> Accredo Specialty Pharmacy**</pre> Prescriber's office stock (billing on a medical claim form) Retail pharmacy Prescriber's office stock (billing on a medical claim form) Home Health / Home Infusion vendor **Cigna's nationally preferred specialty pharmacy **Cigna's nationally preferred specialty pharmacy **Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557 Facility and/or doctor dispensing and administering medication: Facility Name: State: State: Tax ID#:						
Is the patient a candidate f Does the physician have a			Yes 🗌 No 🗌 Yes 🗌 No 🗍			
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?						
Diagnosis related to use? adult T-cell leukemia/lymphoma (ATLL) AIDS-related B cell lymphoma anal carcinoma anal carcinoma of the thyroid diffuse large B cell lymphoma (DLBCL) bladder cancer bone cancer (including Ewing sarcoma or osteosarcoma) breast cancer Burkitt lymphoma central nervous system cancers (including intracranial/spinal ependymoma, astrocytoma, oligodendroglioma, medulloblastoma, anaplastic gliomas, and glioblastoma) cervical cancer epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer esophageal/esophageal junction cancer extranodal NK/T-cell lymphoma, nasal type follicular lymphoma gastric cancer gestational trophoblastic neoplasia hepatosplenic gamma-delta T-cell lymphoma						

histologic transformation of marginal zone lymphoma (MZL) to diffuse large B cell lymph Hodgkin's lymphoma kidney cancer (renal cancer, renal cell carcinoma, RCC) malignant pleural mesothelioma mantle cell lymphoma Merkel cell carcinoma Merkel cell carcinoma Merkel cell carcinoma mycosis fungoides (MF)/Sezary syndrome (SS) neuroendocrine tumors non-small cell lung cancer (NSCLC) occult primary-adenocarcinoma not otherwise specified peripheral T cell lymphoma pilocytic astrocytoma post-transplant lymphoproliferative disorder (PTLD) primary cutaneous CD30+ T-cell lymphoproliferative disorder prostate cancer thabdomyosarcoma small cell lung cancer (SCLC) squamous cell carcinoma of the head and neck cancer (SCCHN) subependymoma testicular cancer hymoma/thymic carcinoma uterine/endometrial carcinoma uveal melanoma vulvar cancer other (please specify): Clinical Information (if anal cell carcinoma or breast cancer) Does your patient have metastatic disease? (if breast cancer and not metastatic) Will carboplatin be used as neoadjuvant or adjuvant if breast cancer and not metastatic) Will carboplatin be used as neoadjuvant or adjuvant if breast cancer and not metastatic) Will carboplatin be used as neoadjuvant or adjuvant if breast cancer and not metastatic) Will carboplatin be used as neoadjuvant or adjuvant if breast cancer and not metastatic) Will carboplatin be used as neoadjuvant or adjuvant if breast cancer and not metastatic) Will carboplatin be used as neoadjuvant or adjuvant if breast cancer and not metastatic) Does your patient have human epidermal growth fac Additional pertinent information (please include disease stage, prior therapy, performant schedule of any agents to be used concurrently):	Yes No t chemotherapy? Yes No which is Taxotere [docetaxel], Carboplatin, Yes No ctor receptor 2 (HER2) positive disease? Yes No
Attestation: I attest the information provided is true and accurate to the best of my knowl	
insurer its designees may perform a routine audit and request the medical information information reported on this form. Prescriber Signature:	Date:
Save Time! Submit Online at: <u>www.covermymeds.com/main/prior-authorization-form</u>	ns/cigna/ or via SureScripts in your EHR.
Our standard response time for prescription drug coverage requests is 5 business days.	
you call us to expedite the request. View our Prescription Drug List and Covera	age Policies online at cigna.com.
	v010124

v010 "Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005